Shulin Li

List of Publications by Year
in descending order

90 papers	5,865 citations	109321 35 h-index	76900 74 g-index
94 all docs	94 docs citations	94 times ranked	10496 citing authors

#	Article	IF	Citations
1	Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. , 2022, 10, e003633.		19
2	Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. Clinical Cancer Research, 2022, 28, 3862-3873.	7.0	3
3	Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Science Advances, 2021, 7, .	10.3	54
4	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology, 2021, 18, 435-453.	27.6	31
5	Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance. Cancer Letters, 2021, 502, 143-153.	7.2	8
6	FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Letters, 2021, 506, 83-94.	7.2	25
7	WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nature Communications, 2021, 12, 3500.	12.8	28
8	Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Frontiers in Oncology, 2021, 11, 760267.	2.8	5
9	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematology,the, 2020, 7, e61-e72.	4.6	56
10	The Organ Trail: A Review of Biomarkers of Organ Failure. Frontiers in Oncology, 2020, 10, 579219.	2.8	2
11	Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer, 2020, 20, 715.	2.6	9
12	Antiâ€“PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clinical Cancer Research, 2020, 26, 4699-4712.	7.0	65
13	Cell surface vimentinâ€positive circulating tumor cellâ€based relapse prediction in a longâ€term longitudinal study of postremission neuroblastoma patients. International Journal of Cancer, 2020, 147, 3550-3559.	5.1	19
14	Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFÎ² Signaling. Cancer Research, 2020, 80, 1819-1832.	0.9	17
15	Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy. Advances in Experimental Medicine and Biology, 2020, 1257, 169-178.	1.6	4
16	The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. Journal of the National Cancer Institute, 2019, 111, 292-300.	6.3	32
17	Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. Oncogene, 2019, 38, 7433-7446.	5.9	4
18	CTC analysis: an update on technological progress. Translational Research, 2019, 212, 14-25.	5.0	20

#	Article	IF	Citations
19	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nature Communications, 2019, 10, 448.	12.8	65
20	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. , 2019, 7, 154.		16
21	Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment. Expert Opinion on Therapeutic Targets, 2019, 23, 647-649.	3.4	3
22	A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure. Translational Research, 2019, 205, 44-50.	5.0	5
23	Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. Journal of Allergy and Clinical Immunology, 2019, 143, 346-358.e6.	2.9	59
24	T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. Clinical Cancer Research, 2018, 24, 2920-2934.	7.0	58
25	Cell-surface vimentinâ€“positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. OncoImmunology, 2018, 7, e1420450.	4.6	28
26	Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-Î² Pathway. Gastroenterology, 2018, 154, 195-210.	1.3	105
27	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
28	Patchable micro/nanodevices interacting with skin. Biosensors and Bioelectronics, 2018, 122, 189-204.	10.1	47
29	Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Letters, 2018, 433, 176-185.	7.2	28
30	Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. Journal of Clinical Investigation, 2018, 129, 137-149.	8.2	242
31	A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS ONE, 2018, 13, e0193485.	2.5	8
32	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research, 2017, 5, 300-311.	3.4	20
33	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology, 2017, 19, 1047-1057.	1.2	325
34	Transforming growth factorâ€Î² in liver cancer stem cells and regeneration. Hepatology Communications, 2017, 1, 477-493.	4.3	30
35	Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Letters, 2017, 403, 216-223.	7.2	29
36	IL6â€mediated inflammatory loop reprograms normal to epithelialâ€mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor betaâ€“deficient Î²2â€spectrin+/â˜’ mice. Hepatology, 2017, 65, 1222-1236.	7.3	56

#	Article	IF	Citations
37	EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. Oncotarget, 2017, 8, 49329-49337.	1.8	105
38	Alcohol, stem cells and cancer. Genes and Cancer, 2017, 8, 695-700.	1.9	9
39	Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells. Journal of Cancer, 2016, 7, 1824-1832.	2.5	22
40	Mutational Profiles Reveal an Aberrant TGF-Î²-CEA Regulated Pathway in Colon Adenomas. PLoS ONE, 2016, 11, e0153933.	2.5	17
41	Expression of Concern: The functional role of long non-coding RNAs and epigenetics. Biological Procedures Online, 2016, 18, 12.	2.9	22
42	Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-Î²/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. Scientific Reports, 2016, 6, 30217.	3.3	43
43	Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. Journal of Hepatology, 2016, 64, 1128-1136.	3.7	31
44	Regulation of NKG2D⁺CD8⁺T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. OncoImmunology, 2016, 5, e1252012.	4.6	21
45	Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Scientific Reports, 2016, 6, 28910.	3.3	152
46	Mutant p53 in concert with an interleukinâ€27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology, 2016, 63, 1000-1012.	7.3	29
47	Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clinical Cancer Research, 2016, 22, 3876-3883.	7.0	15
48	Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget, 2016, 7, 72021-72032.	1.8	44
49	IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. Oncotarget, 2016, 7, 77138-77151.	1.8	4
50	Safe and effective treatment of spontaneous neoplasms with interleukin 12 electroâ€chemoâ€gene therapy. Journal of Cellular and Molecular Medicine, 2015, 19, 664-675.	3.6	33
51	EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget, 2015, 6, 10697-10711.	1.8	408
52	Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Communication and Signaling, 2015, 13, 14.	6.5	45
53	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. Journal of the National Cancer Institute, 2015, 107, .	6.3	80
54	Cellâ€surface <scp>V</scp>imentin: <scp>A</scp> mislocalized protein for isolating <scp>csV</scp>imentin⁺<scp>CD</scp>133^{â˜} novel stemâ€like hepatocellular carcinoma cells expressing <scp>EMT</scp> markers. International Journal of Cancer, 2015, 137, 491-496.	5.1	74

#	Article	IF	Citations
55	Epithelialâ€“Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression. Clinical Cancer Research, 2015, 21, 899-906.	7.0	199
56	Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Moleculeâ€“ and Cell-Surface Vimentinâ€“Based Methods for Monitoring Breast Cancer Therapeutic Response. Clinical Chemistry, 2015, 61, 259-266.	3.2	151
57	The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. International Reviews of Immunology, 2014, 35, 1-15.	3.3	41
58	ILâ€30 (IL27p28) attenuates liver fibrosis through inducing NKG2Dâ€rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology, 2014, 60, 2027-2039.	7.3	105
59	Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: An underappreciated symbiotic relationship. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 152-160.	7.4	13
60	Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biological Procedures Online, 2014, 16, 3.	2.9	7
61	Protein mislocalization: Mechanisms, functions and clinical applications in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 13-25.	7.4	57
62	CD8+T cellâ€“specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Molecular Cancer, 2014, 13, 34.	19.2	29
63	Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research, 2014, 74, 1645-1650.	0.9	139
64	The Role of the Liver in Sepsis. International Reviews of Immunology, 2014, 33, 498-510.	3.3	371
65	Managing Local Swelling Following Intratumoral Electro-Chemo-Gene Therapy. Methods in Molecular Biology, 2014, 1121, 233-239.	0.9	1
66	The Impact of Non-electrical Factors on Electrical Gene Transfer. Methods in Molecular Biology, 2014, 1121, 47-54.	0.9	6
67	Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions. Current Gene Therapy, 2014, 15, 44-54.	2.0	19
68	The cell-to-cell coordination between activated T cells and CpG-stimulated macrophages synergistically induce elevated levels of IL-10 via NF-Î²B1, STAT3, and CD40/CD154. Cell Communication and Signaling, 2013, 11, 95.	6.5	11
69	Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies. Cancer Letters, 2013, 329, 68-73.	7.2	4
70	Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends in Biotechnology, 2013, 31, 347-354.	9.3	164
71	Intricacies for Posttranslational Tumor-Targeted Cytokine Gene Therapy. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	5
72	Coordination between TLR9 Signaling in Macrophages and CD3 Signaling in T Cells Induces Robust Expression of IL-30. Journal of Immunology, 2012, 188, 3709-3715.	0.8	26

#	Article	IF	Citations
73	Competitive DNA transfection formulation via electroporation for human adipose stem cells and mesenchymal stem cells. Biological Procedures Online, 2012, 14, 7.	2.9	11
74	Interleukin-30: A novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology, 2012, 55, 1204-1214.	7.3	46
75	WSX1 Expression in Tumors Induces Immune Tolerance via Suppression of Effector Immune Cells. PLoS ONE, 2011, 6, e19072.	2.5	8
76	Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and Molecular Life Sciences, 2011, 68, 3033-3046.	5.4	1,192
77	Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and Treatment of Distal Tumors by IL-12 Gene Therapy. Molecular Therapy, 2011, 19, 1468-1477.	8.2	48
78	Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis. PLoS ONE, 2011, 6, e23270.	2.5	8
79	Expression of WSX1 in Tumors Sensitizes IL-27 Signaling-Independent Natural Killer Cell Surveillance. Cancer Research, 2009, 69, 5505-5513.	0.9	31
80	Passive and Active Tumor Homing Cytokine Therapy. , 2009, , 97-113.		2
81	Electroporation Protocols. Methods in Molecular Biology, 2008, 423, v-vii.	0.9	13
82	Administering Plasmid DNA Encoding Tumor Vesselâ€“anchored IFN-Î± for Localizing Gene Product Within or Into Tumors. Molecular Therapy, 2008, 16, 901-906.	8.2	20
83	Intratumoral Bleomycin and IL-12 Electrochemogenetherapy for Treating Head and Neck Tumors in Dogs. Methods in Molecular Biology, 2008, 423, 319-325.	0.9	45
84	Doxorubicin Directs the Accumulation of Interleukin-12â€“Induced IFNÎ³ into Tumors for Enhancing STAT1â€“Dependent Antitumor Effect. Clinical Cancer Research, 2007, 13, 4252-4260.	7.0	31
85	Regression of High-Grade Malignancy in Mice by Bleomycin and Interleukin-12 Electrochemogenetherapy. Clinical Cancer Research, 2006, 12, 257-263.	7.0	47
86	Administration Route- and Immune Cell Activation-Dependent Tumor Eradication by IL12 electrotransfer. Molecular Therapy, 2005, 12, 942-949.	8.2	36
87	Regression of Tumor Growth and Induction of Long-Term Antitumor Memory by Interleukin 12 Electro-Gene Therapy. Journal of the National Cancer Institute, 2002, 94, 762-768.	6.3	65
88	Applications of Muscle Electroporation Gene Therapy. Current Gene Therapy, 2002, 2, 101-105.	2.0	32
89	Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Therapy, 2001, 8, 151-157.	4.6	51
90	IL-12-Based therapy of malignancies. Drugs of Today, 2001, 37, 629.	1.1	5